Thanks, interesting post, but Schrodinger and Abcellear have pipelines, so they are not "just" service companies, certainly. Also, Cyclica was acquired a couple years ago by Recursion.
Great post, But what would you consider a fund raising strategy for a biologics platform company ( platform already running) that needs just 7-10 M for setting up labs, and another 10-14 M for optimising say 2-3 candidates. The problem is that you need at least 24 M to come out with a product, How would you approach investors asking for a 24 M at one go, or asking 7-10 to set up labs etc. Any thoughts?
Thanks, interesting post, but Schrodinger and Abcellear have pipelines, so they are not "just" service companies, certainly. Also, Cyclica was acquired a couple years ago by Recursion.
https://www.baybridgebio.com/blog/platform-underperform.html
Great post, But what would you consider a fund raising strategy for a biologics platform company ( platform already running) that needs just 7-10 M for setting up labs, and another 10-14 M for optimising say 2-3 candidates. The problem is that you need at least 24 M to come out with a product, How would you approach investors asking for a 24 M at one go, or asking 7-10 to set up labs etc. Any thoughts?